Navidea brings Lymphoseek to U.S. market

05/1/2013 | Wall Street Journal, The

Navidea Biopharmaceuticals is launching its lymphatic mapping radiopharmaceutical Lymphoseek in the U.S., the company announced today. Navidea has partnered with Cardinal Health to distribute the product to U.S. health care providers. "Commercialization of Lymphoseek in the U.S. marks a pivotal milestone for Navidea, and we are pleased to deliver this innovative diagnostic imaging agent to patients with breast cancer and melanoma," said Navidea President and CEO Dr. Mark Pykett. Lymphatic mapping helps trace the spread of cancer.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Compliance Specialist
MJHS
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC
Regulatory Senior Managing/Principal Engineer/Scientist
Exponent
Menlo Park, CA
Director of Claims
Meridian Health Plan
Detroit, MI